Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults
Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study represents the first administration of GSK625433 in humans. The study is designed
to evaluate initial safety and tolerability in healthy adults as well as anti-viral activity
in Hepatitis C(HVC) infected adults. The way the human body processes GSK625433 will also be
investigated.